German biotech HepaRegeniX has raised 21.5 million euros ($23 million) in new funding to support the clinical development of its lead candidate, HRX-215, a first-in-class treatment aimed at enhancing ...

Galapagos (Euronext: GLPG) said on Tuesday that its chief financial officer and chief operating officer Thad Huston will leave the company on August 1, 2025, to return to the USA for personal and ...

Danish pharma major Novo Nordisk says that it has become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside its authorized supply chain in the USA.

Shares in Johnson & Johnson were 1% lower in the early stages of Tuesday’s trading after the US health conglomerate presented its first-quarter 2025 financial results.

Austrian drug delivery specialist Cyprumed GmbH and US pharma giant Merck & Co (NYSE: MRK), known as MSD outside of the USA and Canada, have signed a non-exclusive license and option agreement to ...

Cambridge, USA-based biotech Oak Hill Bio, which is focused on acquiring and developing life-changing rare disease therapeutics, has entered into an exclusive license agreement with Roche (ROG: SIX) ...

New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and ...

Privately-held US biotech Attovia Therapeutics, which is developing treatments for immune-mediated diseases with high unmet patient need, today announced the close of a $90 million Series C financing.

The US Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s (NYSE: ABBV) mega blockbuster drug Humira (adalimumab), to treat eight ...

French pharma major Sanofi (Euronext: SAN) has shared new progress from its mid- to late-stage respiratory pipeline. The Paris-based company has presented new Phase II data on amlitelimab, showing its ...

US pharma major Bristol Myers Squibb (NYSE: BMY) yesterday disclosed that its Phase III ODYSSEY-HCM trial of Camzyos (mavacamten) did not meet its primary endpoints for treating non-obstructive ...

German family-owned drug major Boehringer Ingelheim and Cue Biopharma (Nasdaq: CUE) have announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s ...